These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Inotropic drugs for treatment of the failing heart. Maskin CS; Le Jemtel TH; Sonnenblick EH Cardiovasc Clin; 1984; 14(3):1-17. PubMed ID: 6327040 [No Abstract] [Full Text] [Related]
4. New positive inotropic agents. Jafri SM; Bristol JA Henry Ford Hosp Med J; 1986; 34(3):188-92. PubMed ID: 3542907 [No Abstract] [Full Text] [Related]
5. Effect of intravenous positive inotropic therapy on myocardial damage in patients with dilated cardiomyopathy. Albayrak F; Demircan S; Yazici M; Arslandağ M Anadolu Kardiyol Derg; 2008 Feb; 8(1):69. PubMed ID: 18258539 [No Abstract] [Full Text] [Related]
6. [Principles, methods and criteria for assessing the effectiveness of potentially cardiotonic compounds at the preclinical research stage]. Chekman IS; Tkachuk VV Farmakol Toksikol; 1984; 47(6):5-15. PubMed ID: 6394358 [No Abstract] [Full Text] [Related]
7. [Positive inotropic agents in heart failure. Clinico-pharmacological evidence for medical practice]. Rohde LE; Ribeiro JP Arq Bras Cardiol; 1994 Dec; 63(6):537-42. PubMed ID: 7605243 [No Abstract] [Full Text] [Related]
12. [Calcium sensitizers--a new group of drugs that increase myocardium contractility]. Laine M; Lehtonen L; Nieminen MS Duodecim; 2000; 116(20):2181-3. PubMed ID: 12017622 [No Abstract] [Full Text] [Related]
13. [Congestive cardiomyopathy: basal hemodynamics and hemodynamics after various positive inotropic drugs administered singly or in combinations]. Cappello C; Fusaro MT; Mattioli G Cardiologia; 1988 Dec; 33(12):1127-32. PubMed ID: 3076518 [No Abstract] [Full Text] [Related]
14. Between Scylla and Charybdis: The choice of inotropic agent for decompensated heart failure. Felker GM; O'connor CM Am Heart J; 2001 Dec; 142(6):932-3. PubMed ID: 11717593 [No Abstract] [Full Text] [Related]
15. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy. Stevenson LW Circulation; 2003 Jul; 108(4):492-7. PubMed ID: 12885733 [No Abstract] [Full Text] [Related]
16. Rationale and design of the enoximone clinical trials program. Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960 [TBL] [Abstract][Full Text] [Related]
17. The search for the ideal positive inotropic agent. Packer M N Engl J Med; 1993 Jul; 329(3):201-2. PubMed ID: 8515793 [No Abstract] [Full Text] [Related]